BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mozafari N, Azadi S, Mehdi-Alamdarlou S, Ashrafi H, Azadi A. Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin. Med Hypotheses 2020;143:110111. [PMID: 32721805 DOI: 10.1016/j.mehy.2020.110111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Han T, Ma S, Sun C, Zhang H, Qu G, Chen Y, Cheng C, Chen EL, Ayaz Ahmed M, Kim KY, Manem R, Chen M, Guo Z, Yang H, Yan Y, Zhou Q. The Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis. Archives of Medical Research 2021. [DOI: 10.1016/j.arcmed.2021.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mozafari N, Ashrafi H, Azadi A. Targeted drug delivery systems to control neuroinflammation in central nervous system disorders. Journal of Drug Delivery Science and Technology 2021;66:102802. [DOI: 10.1016/j.jddst.2021.102802] [Reference Citation Analysis]
3 Bagheri A, Moezzi SMI, Mosaddeghi P, Nadimi Parashkouhi S, Fazel Hoseini SM, Badakhshan F, Negahdaripour M. Interferon-inducer antivirals: Potential candidates to combat COVID-19. Int Immunopharmacol 2021;91:107245. [PMID: 33348292 DOI: 10.1016/j.intimp.2020.107245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
4 Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab 2021;47:101213. [PMID: 33249199 DOI: 10.1016/j.diabet.2020.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
5 Babajani A, Hosseini-Monfared P, Abbaspour S, Jamshidi E, Niknejad H. Targeted Mitochondrial Therapy With Over-Expressed MAVS Protein From Mesenchymal Stem Cells: A New Therapeutic Approach for COVID-19. Front Cell Dev Biol 2021;9:695362. [PMID: 34179022 DOI: 10.3389/fcell.2021.695362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hariharan A, Hakeem AR, Radhakrishnan S, Reddy MS, Rela M. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. Inflammopharmacology. 2021;29:91-100. [PMID: 33159646 DOI: 10.1007/s10787-020-00773-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 21.5] [Reference Citation Analysis]
7 Sahukari R, Punabaka J, Bhasha S, Ganjikunta VS, Kondeti Ramudu S, Kesireddy SR, Ye W, Korivi M. Phytochemical Profile, Free Radical Scavenging and Anti-Inflammatory Properties of Acalypha Indica Root Extract: Evidence from In Vitro and In Vivo Studies. Molecules 2021;26:6251. [PMID: 34684831 DOI: 10.3390/molecules26206251] [Reference Citation Analysis]
8 Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology 2022. [PMID: 35505267 DOI: 10.1007/s10787-022-00992-2] [Reference Citation Analysis]
9 Morales-Franco B, Nava-Villalba M, Medina-Guerrero EO, Sánchez-Nuño YA, Davila-Villa P, Anaya-Ambriz EJ, Charles-Niño CL. Host-Pathogen Molecular Factors Contribute to the Pathogenesis of Rhizopus spp. in Diabetes Mellitus. Curr Trop Med Rep 2021;:1-12. [PMID: 33500877 DOI: 10.1007/s40475-020-00222-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hegazy WAH, Rajab AAH, Abu Lila AS, Abbas HA. Anti-diabetics and antimicrobials: Harmony of mutual interplay. World J Diabetes 2021; 12(11): 1832-1855 [PMID: 34888011 DOI: 10.4239/wjd.v12.i11.1832] [Reference Citation Analysis]
11 Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, Abdul Ghani M, Abubaker J. Impact of Diabetes in Patients Diagnosed With COVID-19. Front Immunol 2020;11:576818. [PMID: 33335527 DOI: 10.3389/fimmu.2020.576818] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
12 Landstra CP, de Koning EJP. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front Endocrinol (Lausanne) 2021;12:649525. [PMID: 34220706 DOI: 10.3389/fendo.2021.649525] [Reference Citation Analysis]
13 Al-Rabia MW, Alhakamy NA, Ahmed OAA, Eljaaly K, Aloafi AL, Mostafa A, Asfour HZ, Aldarmahi AA, Darwish KM, Ibrahim TS, Fahmy UA. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies. Pharmaceutics 2021;13:307. [PMID: 33652894 DOI: 10.3390/pharmaceutics13030307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Ourani-Pourdashti S, Azadi A. Pollens in therapeutic/diagnostic systems and immune system targeting. J Control Release 2021;340:308-17. [PMID: 34763004 DOI: 10.1016/j.jconrel.2021.11.008] [Reference Citation Analysis]
15 Okai CA, Wölter M, Russ M, Koy C, Petre BA, Rath W, Pecks U, Glocker MO. Profiling of intact blood proteins by matrix-assisted laser desorption/ionization mass spectrometry without the need for freezing - Dried serum spots as future clinical tools for patient screening. Rapid Commun Mass Spectrom 2021;35:e9121. [PMID: 33955049 DOI: 10.1002/rcm.9121] [Reference Citation Analysis]
16 Xie LM, Huang YF, Liu YL, Liang JQ, Deng W, Lin GL, Luo HM, Guo XG. Identification of the Hub Genes and the Signaling Pathways in Human iPSC-Cardiomyocytes Infected by SARS-CoV-2. Biochem Genet 2022. [PMID: 35235083 DOI: 10.1007/s10528-022-10206-7] [Reference Citation Analysis]
17 Memiş H, Çakır A, DurmuŞ M, GÖk S, Bahçeciȯğlu ÖF. Is sitagliptin effective for the treatment of COVID-19? Eur J Hosp Pharm 2021:ejhpharm-2021-002702. [PMID: 33504509 DOI: 10.1136/ejhpharm-2021-002702] [Reference Citation Analysis]
18 Mikhael EM, Ong SC, Sheikh Ghadzi SM. Efficacy and Safety of Sitagliptin in the Treatment of COVID-19. J Pharm Pract 2022;:8971900221102119. [PMID: 35581701 DOI: 10.1177/08971900221102119] [Reference Citation Analysis]
19 Kumar A, Loharch S, Kumar S, Ringe RP, Parkesh R. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2. Comput Struct Biotechnol J 2021;19:424-38. [PMID: 33391634 DOI: 10.1016/j.csbj.2020.12.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Wang Z, Zhang J, Zhan J, Gao H. Screening out anti-inflammatory or anti-viral targets in Xuanfei Baidu Tang through a new technique of reverse finding target. Bioorg Chem 2021;116:105274. [PMID: 34455301 DOI: 10.1016/j.bioorg.2021.105274] [Reference Citation Analysis]
21 Belice T, Demir I. The gender differences as a risk factor in diabetic patients with COVID-19. Iran J Microbiol. 2020;12:625-628. [PMID: 33613918 DOI: 10.18502/ijm.v12i6.5038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Miftode E, Miftode L, Coman I, Prepeliuc C, Obreja M, Stămăteanu O, Părângă TG, Leca D, Pleşca CE. Diabetes Mellitus-A Risk Factor for Unfavourable Outcome in COVID-19 Patients-The Experience of an Infectious Diseases Regional Hospital. Healthcare (Basel) 2021;9:788. [PMID: 34201473 DOI: 10.3390/healthcare9070788] [Reference Citation Analysis]
23 Liskova A, Samec M, Koklesova L, Samuel SM, Zhai K, Al-Ishaq RK, Abotaleb M, Nosal V, Kajo K, Ashrafizadeh M, Zarrabi A, Brockmueller A, Shakibaei M, Sabaka P, Mozos I, Ullrich D, Prosecky R, La Rocca G, Caprnda M, Büsselberg D, Rodrigo L, Kruzliak P, Kubatka P. Flavonoids against the SARS-CoV-2 induced inflammatory storm. Biomed Pharmacother 2021;138:111430. [PMID: 33662680 DOI: 10.1016/j.biopha.2021.111430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]